These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34246985)

  • 41. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
    Pollock NI; Grandis JR
    Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
    Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
    Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.
    Dinkova-Kostova AT; Talalay P
    Arch Biochem Biophys; 2010 Sep; 501(1):116-23. PubMed ID: 20361926
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
    Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
    Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.
    Kolesar JM; Dahlberg SE; Marsh S; McLeod HL; Johnson DH; Keller SM; Schiller JH
    Oncol Rep; 2011 Jun; 25(6):1765-72. PubMed ID: 21479364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
    Isaacsson Velho PH; Castro G; Chung CH
    Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma.
    Mizumoto A; Ohashi S; Kamada M; Saito T; Nakai Y; Baba K; Hirohashi K; Mitani Y; Kikuchi O; Matsubara J; Yamada A; Takahashi T; Lee H; Okuno Y; Kanai M; Muto M
    J Gastroenterol; 2019 Aug; 54(8):687-698. PubMed ID: 30737573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer Stem Cell based molecular predictors of tumor recurrence in Oral squamous cell carcinoma.
    Mohanta S; Sekhar Khora S; Suresh A
    Arch Oral Biol; 2019 Mar; 99():92-106. PubMed ID: 30641296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
    Colucci MA; Moody CJ; Couch GD
    Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p16, pRb, and p53 in Feline Oral Squamous Cell Carcinoma.
    Supsavhad W; Dirksen WP; Hildreth BE; Rosol TJ
    Vet Sci; 2016 Aug; 3(3):. PubMed ID: 29056726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.
    Birkeland AC; Yanik M; Tillman BN; Scott MV; Foltin SK; Mann JE; Michmerhuizen NL; Ludwig ML; Sandelski MM; Komarck CM; Carey TE; Prince ME; Bradford CR; McHugh JB; Spector ME; Brenner JC
    JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):559-67. PubMed ID: 27077364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
    Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
    Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress in targeted therapeutic drugs for oral squamous cell carcinoma.
    Liu L; Chen J; Cai X; Yao Z; Huang J
    Surg Oncol; 2019 Dec; 31():90-97. PubMed ID: 31550560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis, and biological evaluation of 3-(1-benzotriazole)-nor-β-lapachones as NQO1-directed antitumor agents.
    Wu LQ; Ma X; Liu ZP
    Bioorg Chem; 2021 Aug; 113():104995. PubMed ID: 34034133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
    Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
    Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
    Gustafson DL; Beall HD; Bolton EM; Ross D; Waldren CA
    Mol Pharmacol; 1996 Oct; 50(4):728-35. PubMed ID: 8863816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Virtual Screening for Potential Phytobioactives as Therapeutic Leads to Inhibit NQO1 for Selective Anticancer Therapy.
    Shreevatsa B; Dharmashekara C; Swamy VH; Gowda MV; Achar RR; Kameshwar VH; Thimmulappa RK; Syed A; Elgorban AM; Al-Rejaie SS; Ortega-Castro J; Frau J; Flores-Holguín N; Shivamallu C; Kollur SP; Glossman-Mitnik D
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34833955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).
    Megarity CF; Abdel-Aal Bettley H; Caraher MC; Scott KA; Whitehead RC; Jowitt TA; Gutierrez A; Bryce RA; Nolan KA; Stratford IJ; Timson DJ
    Chembiochem; 2019 Nov; 20(22):2841-2849. PubMed ID: 31165578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
    Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
    Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.